150 related articles for article (PubMed ID: 20015010)
1. Gestational trophoblastic neoplasia, an ancient disease: new light and potential therapeutic targets.
Alazzam M; Tidy J; Hancock BW; Powers H
Anticancer Agents Med Chem; 2010 Feb; 10(2):176-85. PubMed ID: 20015010
[TBL] [Abstract][Full Text] [Related]
2. Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets.
Shih IeM
Lancet Oncol; 2007 Jul; 8(7):642-50. PubMed ID: 17613426
[TBL] [Abstract][Full Text] [Related]
3. 15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage.
Brown J; Naumann RW; Seckl MJ; Schink J
Gynecol Oncol; 2017 Jan; 144(1):200-207. PubMed ID: 27743739
[TBL] [Abstract][Full Text] [Related]
4. Genetics of gestational trophoblastic neoplasia: an update for the clinician.
Alifrangis C; Seckl MJ
Future Oncol; 2010 Dec; 6(12):1915-23. PubMed ID: 21142864
[TBL] [Abstract][Full Text] [Related]
5. Reproductive Outcomes After Gestational Trophoblastic Neoplasia. A Comparison Between Single-Agent and Multiagent Chemotherapy: Retrospective Analysis From the MITO-9 Group.
Cioffi R; Bergamini A; Gadducci A; Cormio G; Giorgione V; Petrone M; Rabaiotti E; Pella F; Candiani M; Mangili G
Int J Gynecol Cancer; 2018 Feb; 28(2):332-337. PubMed ID: 29324534
[TBL] [Abstract][Full Text] [Related]
6. Optimal management of low-risk gestational trophoblastic neoplasia.
Goldstein DP; Berkowitz RS; Horowitz NS
Expert Rev Anticancer Ther; 2015; 15(11):1293-304. PubMed ID: 26517533
[TBL] [Abstract][Full Text] [Related]
7. Improving single-agent chemoresistance risk identification in gestational trophoblastic neoplasia.
Ferrandina G; Scambia G
Lancet Oncol; 2021 Aug; 22(8):1054-1056. PubMed ID: 34181885
[No Abstract] [Full Text] [Related]
8. Gestational trophoblastic neoplasia: a meta-analysis evaluating reproductive and obstetrical outcomes after administration of chemotherapy.
Tranoulis A; Georgiou D; Sayasneh A; Tidy J
Int J Gynecol Cancer; 2019 Jul; 29(6):1021-1031. PubMed ID: 31253638
[TBL] [Abstract][Full Text] [Related]
9. Early pregnancy following multidrug regimen chemotherapy in a gestational trophoblastic neoplasia patient: A case report.
Niu G; Yuan LJ; Gong FQ; Yang J; Zhu CX; Shen HW
Medicine (Baltimore); 2017 Dec; 96(51):e9221. PubMed ID: 29390471
[TBL] [Abstract][Full Text] [Related]
10. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13.
Bolze PA; Riedl C; Massardier J; Lotz JP; You B; Schott AM; Hajri T; Golfier F
Am J Obstet Gynecol; 2016 Mar; 214(3):390.e1-8. PubMed ID: 26433171
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcome of patients with gestational trophoblastic neoplasia receiving primary treatment at Peking Union Medical College Hospital: a 30-year retrospective cohort study].
Jiang F; Yang Y; Ji ML; Yang JJ; Zhao J; Ren T; Feng FZ; Wan XR; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):364-370. PubMed ID: 29961277
[No Abstract] [Full Text] [Related]
12. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
[TBL] [Abstract][Full Text] [Related]
13. [Gestational trophoblastic neoplasia].
Langmár Z; Németh M
Orv Hetil; 2011 Dec; 152(49):1971-3. PubMed ID: 22106165
[No Abstract] [Full Text] [Related]
14. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
Mao Y; Wan X; Lv W; Xie X
Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
[TBL] [Abstract][Full Text] [Related]
15. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia.
Ghorani E; Kaur B; Fisher RA; Short D; Joneborg U; Carlson JW; Akarca A; Marafioti T; Quezada SA; Sarwar N; Seckl MJ
Lancet; 2017 Nov; 390(10110):2343-2345. PubMed ID: 29185430
[No Abstract] [Full Text] [Related]
17. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
18. The role of hysterotomy in the management of gestational trophoblastic neoplasia.
Tjalma WA; Vermorken JB
Int J Gynecol Cancer; 2006; 16(2):882-3. PubMed ID: 16681777
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
[TBL] [Abstract][Full Text] [Related]
20. The added value of hysterectomy in the management of gestational trophoblastic neoplasia.
Eysbouts YK; Massuger LFAG; IntHout J; Lok CAR; Sweep FCGJ; Ottevanger PB
Gynecol Oncol; 2017 Jun; 145(3):536-542. PubMed ID: 28390821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
